Skip to main content

Testing version — LOERadar is in active testing. Features and data may change.

Hub News Changes Search

LOERadar

FDA drug patent and exclusivity intelligence, assembled from public records.

Sponsored by

About Terms of Service Privacy Policy Log in

Attorney Advertising

© 2026 LOERadar · An informational research tool drawn from public records; it is not a law firm, does not provide legal advice, and its use does not create an attorney-client relationship.

SUMATRIPTAN AND NAPROXEN SODIUM (NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE) | LOERadar

Viewing data from:

SUMATRIPTAN AND NAPROXEN SODIUM

ANDA

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE | A090872 | RISING PHARMA HOLDINGS INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: TREXIMET(TE code: AB)

Products (1)

#001 — 500MG;EQ 85MG BASE

AB

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Sep 4, 2018

No patent or exclusivity listings for this strength.